Rostock, Germany-based Centogene AG has unveiled a 24-month global study to look at the genetic factors in Parkinson's disease (PD), which affects about 1% of individuals older than 60. Specifically, the Rostock International Parkinson's Disease (ROPAD) study, which will involve up to 10,000 patients, will investigate the genetic background of PD patients for a better understanding of disease development, diagnosis, and treatment.

Alivecor Inc. has received U.S. FDA clearance for a six-lead ECG known as Kardiamobile 6L. It will start retailing in mid-June for $149 but is available for preorder. This is slated to complement the existing one-lead product Kardiamobile, which sells for $99 and has started to face competition with single-lead ECG watch products from Apple Inc. and Verily Life Sciences LLC.